Tag: Innate
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH65… –...
IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell...
Innate Pharma to Hold Its Annual General Meeting of Shareholders on...
The Annual General Meeting will be broadcasted live by the Company
Innate Pharma SA IPHIPHA ("Innate" or the "Company") will hold its Annual General...
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregis… –...
Innate Pharma SA IPHIPHA ("Innate" or the "Company") today announced the filing of its 2022 Universal Registration Document (Document d'enregistrement universel) for the...
Innate Pharma Provides Update on Silicon Valley Bank Exposure – Innate...
Innate Pharma does not have any financial exposure to Silicon Valley Bank
Innate Pharma SA IPHIPHA ("Innate" or the "Company") has learned that Silicon...
Innate Pharma to Participate in Upcoming Investor Conferences – Innate Pharma...
Innate Pharma SA IPHIPHA ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the...